The U.S. Food and Drug Administration (FDA) has granted approval to darolutamide

Read more

Oral Darolutamide presentation at ASCO on 31 May 2019

Impact of Darolutamide on Pain and Quality of Life in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer (nmCRPC) at ASCO taking place in Chicago.

Read more

Capital Markets Day 2019

Orion's Capital Markets Day was held on Wednesday 22 May 2019.

Read more

Half Year Report 2019

Orion published Half Year Report 2019 on Wednesday 17 July 2019.

Darolutamide submitted for marketing authorization also in Europe

8 Mar 2019 I Marketing authorization application has been submitted to EMA. The rolling submission to the FDA in the U.S. was recently completed and the application has also been submitted in the MHLW in Japan.

Read more

Financial Statements 2018

Published on 4 March 2019 I The Financial Statement documents 2018 include the Financial Statements, the Report of the Board of Directors and the Auditor’s Report.

Read more

Scientific article on ARAMIS study published in the New England Journal of Medicine

Read more

AGM 2019

The 2019 Annual General Meeting was held on 26 March 2019 in Helsinki. Read more here.

Read more

Stock Exchange Releases

8/7/2019 Sales of darolutamide started in the USA – Orion receives EUR 45 million milestone
7/31/2019 U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancer (nmCRPC)
7/15/2019 Orion completes enrollment in the REFALS Phase 3 trial studying the effect of oral Levosimendan in patients with amyotrophic lateral sclerosis (ALS)
6/27/2019 Publishing of Orion Corporation's Half Year Report for January-June 2019 on 17 July 2019

Latest investor presentation

Press Releases

8/7/2019 Sales of darolutamide started in the USA – Orion receives EUR 45 million milestone
7/31/2019 U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancer (nmCRPC)
7/15/2019 Orion completes enrollment in the REFALS Phase 3 trial studying the effect of oral Levosimendan in patients with amyotrophic lateral sclerosis (ALS)
6/27/2019 Publishing of Orion Corporation's Half Year Report for January-June 2019 on 17 July 2019

Share information

Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.

Read more

Major shareholders by votes

Monthly updated list of Orion's major shareholders by votes.

Read more

Orion's R&D Pipeline

Read more
Research 

Orion Executive Management Board

The members of the Board of Directors

Orion included in FTSE4Good Index

Orion Corporation has been included in the globally recognised FTSE4Good Index.

Read more

Our approach to corporate responsibility
Orion's century
About Orion
Products and Services
Investors
Media
Corporate Governance
AGM
Sustainability
Contact us